Acromegaly
📧 Sign up to get email alerts when something new happens for Acromegaly.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-09-20Clinical Trial Update: Brain-gut Interaction in Irradiated Patients With Acromegaly
An ongoing clinical trial evaluating brain-gut interactions in patients with acromegaly who have received irradiation; the current trial sta…
-
CLINICAL_TRIALS trial_result · 2016-08-03Clinical Trial Update: Pasireotide LAR and Pegvisomant Study in Acromegaly [Phase 4]
Phase 4 trial update from Erasmus Medical Center evaluating Pasireotide LAR in combination with Pegvisomant for acromegaly; the current stat…
-
FDA approval · 2016-07-22FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis Pharmaceuticals Corporation, resulting in…
-
CLINICAL_TRIALS trial_result · 2016-06-16Clinical Trial Update: Phase II Study With ITF2984 in Acromegalic Patients [Phase 2]
Phase II trial of ITF2984 in acromegaly has completed; no efficacy results are provided in the available summary.
-
FDA approval · 2016-05-20FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis, resulting in changes to the product …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-04-22FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS research · 2016-04-05Clinical Trial Update: Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects [NA]
An update on a completed clinical study examining somatostatin analogue therapy for acromegaly, focusing on molecular aspects.
-
FDA approval · 2016-02-22FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly [Phase 2]
A Phase 2 clinical trial evaluating repeated administration of BIM 23A760 in acromegaly was terminated with results posted in 2016.
-
FDA approval · 2016-01-11FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS approval · 2015-12-29Clinical Trial Update: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
An open-label, multi-center expansion of Pasireotide LAR treatment for acromegaly is discussed, with the product listed as approved for mark…
-
CLINICAL_TRIALS trial_result · 2015-12-14Clinical Trial Update: Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects [Phase 4]
A Phase 4 study assessing the efficacy of an extended injection interval schedule of lanreotide Autogel in people with acromegaly, with resu…
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Surgical Versus Medical Treatment of Acromegaly
A completed clinical trial conducted under University of Aarhus evaluating surgical versus medical treatment for acromegaly.
-
CLINICAL_TRIALS trial_result · 2015-12-01Clinical Trial Update: Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly [Phase 3]
Phase 3 trial results evaluate the efficacy and safety of MYCAPSSA (octreotide) for treating acromegaly. The study completed with results po…
-
FDA approval · 2015-11-02FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2015-06-01FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) filed by Ipsen Biopharmaceuticals, Inc., updating the …
-
CLINICAL_TRIALS trial_result · 2015-04-28Clinical Trial Update: Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues [Phase 4]
This Clinical Trial Update reports on hormonal outcomes in acromegaly patients who have undergone surgery, with or without long-acting somat…
-
FDA approval · 2015-04-15FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for bromocriptine mesylate (Padagis US LLC).
-
CLINICAL_TRIALS trial_result · 2015-03-18Clinical Trial Update: Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment
Clinical trial update on the effects of growth hormone on cardiac function, as measured by echocardiography, in growth hormone-deficient pat…
-
FDA approval · 2015-03-17FDA Approved: SIGNIFOR — Supplemental Application (Recordati Rare Diseases, Inc.)
The FDA approved a supplemental application for Signifor (pasireotide) filed by Recordati Rare Diseases, Inc., potentially expanding its lab…
-
FDA approval · 2015-02-13FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Bromocriptine Mesylate by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2015-01-30Clinical Trial Update: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly [Phase 3]
Phase 3 trial comparing pasireotide long-acting release to octreotide long-acting release in active acromegaly completed with results posted…
-
CLINICAL_TRIALS trial_result · 2015-01-21Clinical Trial Update: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly [Phase 3]
A Phase 3 trial compares pasireotide long-acting release (LAR) with octreotide LAR or lanreotide Autogel in patients with inadequately contr…
-
FDA approval · 2014-12-22FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2014-12-16FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., updating regulato…